

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1. (currently amended) A method for treating irritable bowel syndrome in a subject in need of such treatment, comprising administering to said subject an amount of [a] at least one salt of a polyamine with a pharmaceutically acceptable acid effective to treat irritable bowel syndrome in said subject, said polyamine being selected from the group consisting of [polyamine] polyamines having the formula:

1) [R-NH-(CH₂)_a-NH-(CH₂)_b-H-(CH₂)_c-NH₂,] R-NH-(CH₂)_a-NH-(CH₂)_b-NH-(CH₂)_c-NH₂,

2) CF₃-C₆H₅-(CH₂)_a-NH-(CH₂)_b-NH-(CH₂)_c-NH-(CH₂)_d-NH-(CH₂)_e-C₆H₅-CF₃,

3) [R-NH-(CH₂)_a-NH-C₆H₆-NH-(CH₂)_b-NH-R] R-NH-(CH₂)_a-NH-C₆H₁₀-NH-(CH₂)_b-NH-R, and

4) PIP-(CH₂)_a-NH-(CH₂)_b-NH-(CH₂)_c-PIP,

wherein:

R is alkyl, aryl, aralkyl, alkaryl, or cyclo-alkyl having up to about 10 carbon atoms, and any of said alkyl chains may optionally be interrupted by at least one etheric oxygen atom,

PIP is piperidine and

a, b, c, d, and e may be the same or different and are integers from 1-10.

2. (previously presented) The method of claim 1 wherein said subject is human.
3. (previously presented) The method according to claim 1, wherein said polyamine is administered at a dose between about 0.0001 mg/day and about 500 mg/day.
4. (previously presented) The method according to claim 1, wherein said polyamine is administered in one or more forms selected from the group consisting of orally, parenterally, transdermally, or by suppository.
5. (previously presented) The method according to claim 1, wherein said polyamine is administered orally.
6. (previously presented) The method according to claim 1, wherein said polyamine is administered parenterally.
7. (currently amended) The method according to claim 1, wherein said compound is 1) $[R-NH-(CH_2)_a-NH-(CH_2)_bH-(CH_2)_c-NH_2]$ $R-NH-(CH_2)_a-NH-(CH_2)_bNH-(CH_2)_c-NH_2$.
8. (previously presented) The method according to claim 1, wherein said compound is 2) $CF_3-C_6H_5-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-NH-(CH_2)_d-NH-(CH_2)_e-C_6H_5-CF_3$.

9. (currently amended) The method according to claim 1, wherein said compound is 3) $[R-NH-(CH_2)_a-NH-C_6H_6-NH-(CH_2)_b-NH-R]$ $R-NH-(CH_2)_a-NH-C_6H_{10}-NH-(CH_2)_b-NH-R$.

10. (previously presented) The method according to claim 1, wherein said compound is 4) $PIP-(CH_2)_aNH-(CH_2)_b-NH-(CH_2)_c-PIP$.

11. (currently amended) A pharmaceutical composition in unit dosage form adapted for administration to a subject suffering from irritable bowel syndrome comprising an amount of [a] at least one salt of a polyamine with a pharmaceutically acceptable acid therapeutically effective to treat irritable bowel syndrome and a pharmaceutically acceptable carrier therefore, said polyamine being selected from the group consisting of polyamines having the formula:

1) $[R-NH-(CH_2)_a-NH-(CH_2)_bH-(CH_2)_c-NH_2]$ $R-NH-(CH_2)_a-NH-(CH_2)_bNH-(CH_2)_c-NH_2$,

2) $CF_3-C_6H_5-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-NH-(CH_2)_d-NH-(CH_2)_e-C_6H_5-CF_3$,

3) $[R-NH-(CH_2)_a-NH-C_6H_6-NH-(CH_2)_b-NH-R]$ $R-NH-(CH_2)_a-NH-C_6H_{10}-NH-(CH_2)_b-NH-R$

and

4) $PIP-(CH_2)_aNH-(CH_2)_b-NH-(CH_2)_c-PIP$,

wherein:

R is alkyl, aryl, aralkyl, alkaryl, or cyclo-alkyl having up to 10 about carbon atoms, and any of said alkyl chains may optionally be interrupted by at least one etheric oxygen atom,

PIP is piperidine and

a, b, c, d, and e may be the same or different and are integers from 1-10.

12. (previously presented) The composition according to claim 10 wherein the form thereof is such that it may be administered orally, parenterally, transdermally, or by suppository.

13. (previously presented) The composition according to claim 10 wherein the form thereof is such that it may be administered orally.

14. (previously presented) The composition according to claim 10 wherein the form thereof is such that it may be administered parenterally.

15. (previously presented) The method according to claim 10, wherein said compound is 1) $R-NH-(CH_2)_a-NH-(CH_2)_bH-(CH_2)_c-NH_2$.

16. (previously presented) The method according to claim 10, wherein said compound is 2) $CF_3-C_6H_5-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-NH-(CH_2)_d-NH-(CH_2)_e-C_6H_5-CF_3$.

17. (currently amended) The method according to claim 10, wherein said compound is 3) $[R-NH-(CH_2)_a-NH-C_6H_6-NH-(CH_2)_b-NH-R]$ $R-NH-(CH_2)_a-NH-C_6H_{10}-NH-(CH_2)_b-NH-R$.

18. (previously presented) The method according to claim 10, wherein said compound is 4) $PIP-(CH_2)_aNH-(CH_2)_b-NH-(CH_2)_c-PIP$.

19. (currently amended) An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent is effective for the treatment of a subject suffering from irritable bowel syndrome, and wherein said packaging material comprises a label which indicates that said pharmaceutical agent can be used for ameliorating the symptoms associated with irritable bowel syndrome, and wherein said pharmaceutical agent is at least one salt of a polyamine with a pharmaceutically acceptable acid, the polyamine being selected from the group consisting of polyamines having the formula:

1) $[R-NH-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-NH_2]$ $R-NH-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-$
 NH_2 ,

2) $CF_3-C_6H_5-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-NH-(CH_2)_d-NH-(CH_2)_e-C_6H_5-CF_3$,

3) $R-NH-(CH_2)_a-NH-C_6H_6-NH-(CH_2)_b-NH-R$, and

4) $PIP-(CH_2)_a-NH-(CH_2)_b-NH-(CH_2)_c-PIP$,

wherein:

R is alkyl, aryl, aralkyl, alkaryl, or cyclo-alkyl having up to about 10 carbon atoms, and any of said alkyl chains may optionally be interrupted by at least one etheric oxygen atom,

PIP is piperidine, and

a, b, c, d, and e may be the same or different and are integers from 1-10.